ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0572

Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis

Erdem Gurel1, Suzan Cinar2, Ozge Hurdogan3, Yasemin Ozluk3, Isin Kilicaslan4, Sibel Varelci1, Safak Mirioglu5, Yasemin Yalcinkaya6, Ahmet Gul6, Lale Ocal1, Murat Inanc6 and Bahar Artim-Esen6, 1Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, 2Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 3Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, 4Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbıl, Turkey, 5Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Disease Activity, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is shedded from the cell membrane and becomes soluble CD163. Therefore, it has been shown that serum (s) and urine (u) levels of soluble CD163 increase in acute or chronic inflammatory diseases. sCD163 and uCD163 are considered as potential biomarkers reflecting disease activity in patients with systemic lupus erythematosus (SLE).We aimed to investigate the association of serum and urine soluble CD163 levels and renal CD163 expression with disease activity in patients with lupus nephritis (LN).

Methods: Serum and urine levels of CD163 of 45 SLE patients (active renal 20, active non-renal 15, inactive 10) and 20 healthy volunteers were tested by ELISA. Control samples were taken from 12 active renal patients after six months of treatment and 30 renal biopsy specimens were examined for CD163 expression.

Results: Of 45 participants, 37 (82.2%) were female, with a median disease duration of 113 (1-436) months and a mean age of 38,9±13 (18-68) years. Both the frequency of uCD163 positivity and its levels were significantly higher in the active LN group compared to the inactive LN (p=0,007 and 0.02 respectively) and active non-renal SLE (p=0,001 and 0.023 respectively) groups (Table 1). sCD163 and uCD163 levels of 12 patients with active LN were significantly reduced after treatment (p=0,04 and p=0,006) (Figure 1). CD163+ macrophage expression in kidney biopsies of patients with active LN correlated with sCD163 (r= 0.597 and p=0.01) and uCD163 (r=0.507 and p=0.045) levels.

Conclusion: uCD163 is a promising biomarker that can differentiate active LN from inactive LN and active extrarenal SLE changing in line with treatment response. Correlation of both s and uCD163 with CD163+ macrophage expression in biopsies suggests that it may be used as an activity parameter in patients with lupus nephritis histopathologically. Further studies are awaited to confirm these results.

Supporting image 1

Table 1. Serum and urine levels of CD163 across study groups

Supporting image 2

Figure 1. Serum and urine levels of CD163 after treatment


Disclosures: E. Gurel: None; S. Cinar: None; O. Hurdogan: None; Y. Ozluk: None; I. Kilicaslan: None; S. Varelci: None; S. Mirioglu: None; Y. Yalcinkaya: None; A. Gul: None; L. Ocal: None; M. Inanc: None; B. Artim-Esen: None.

To cite this abstract in AMA style:

Gurel E, Cinar S, Hurdogan O, Ozluk Y, Kilicaslan I, Varelci S, Mirioglu S, Yalcinkaya Y, Gul A, Ocal L, Inanc M, Artim-Esen B. Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/serum-urine-levels-and-expression-of-cd163-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-urine-levels-and-expression-of-cd163-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology